Commercialization of Medical Devices to Reduce the Risk of Thrombosis and Bleeding
First written in FY2022. 6 of 10 entries say "Restated". Latest entry: 2026-09-14.
No other company in this theme has enough history to compare yet.
- 2026-09-14RestatedOther Disclosures
「We will introduce fields in which we are pursuing new solution businesses by leveraging technologies developed through cell-culture process development.」
The company reaffirmed its efforts to develop new solution businesses using cell-culture technologies. - FY2026AdvancedAnnual report
「We will work to develop businesses based on medical devices, products related to in vitro diagnostic reagents, and testing reagents that can become the next-generation earnings base.」
Efforts in the medical device and in vitro diagnostic-related businesses were given concrete form through establishing them as the next-generation earnings base, developing medical devices for in vitro diagnostic reagents, and building the foundation for contract manufacturing of cell-related products. - FY2025AdvancedAnnual report
「In the fields of cell therapy and regenerative medicine, we will continue to promote collaboration with academia and drug-discovery ventures, actively promote the commercialisation of contract cell culture and processing, and support the industrialisation and wider adoption of regenerative medicine products and products related to in vitro diagnostic reagents, which are attracting attention as new modalities (therapeutic and diagnostic methods).」
The policy of investing in the development of medical devices, in vitro diagnostic reagents, and regenerative medicine was given concrete form through the commercialisation of contract cell culture and processing and the promotion of industrialisation and wider adoption. - FY2025-H1RestatedAnnual report
「In terms of earnings, profit declined due to continued development spending on medical devices, products related to in vitro diagnostic reagents, and the regenerative medicine field, among other factors.」
Reconfirmed the continued investment of development costs in medical devices, products related to in vitro diagnostic reagents, and the regenerative medicine field. - FY2024AdvancedAnnual report
「We will continue to invest actively in the medical device and contract cell culture businesses and work to establish a foundation in the biotechnology field.」
The policy of commercialising medical devices to reduce thrombosis and bleeding risks was given concrete form through the global expansion of T-TAS, contract cell culture, and active investment. - FY2024-Q3RestatedAnnual report
「In terms of earnings, profit declined due to lower sales and continued development spending on medical devices, products related to in vitro diagnostic reagents, and the regenerative medicine field, among other factors.」
Reconfirmed the continued investment of upfront development costs in medical devices, products related to in vitro diagnostic reagents, and the regenerative medicine field. - FY2024-Q2RestatedAnnual report
「In terms of earnings, profit declined due to continued upfront development spending on medical devices, products related to in vitro diagnostic reagents, and the regenerative medicine field, among other factors.」
Reconfirmed the continued investment of upfront development costs in medical devices, products related to in vitro diagnostic reagents, and the regenerative medicine field. - FY2024-Q1RestatedAnnual report
「We are also making upfront investments in the development of medical devices and products related to in vitro diagnostic reagents.」
Reconfirmed the continued investment of upfront development costs in medical devices and products related to in vitro diagnostic reagents. - FY2023RestatedAnnual report
「Promotion of the commercialisation of medical devices designed to reduce the risks of thrombosis and bleeding.」
Reconfirmed the commercialisation of medical devices aimed at reducing thrombosis and bleeding risks as a business priority. - FY2022First statedAnnual report
「Promotion of the commercialisation of medical devices designed to reduce the risks of thrombosis and bleeding.」
Explicitly identified the commercialisation of medical devices aimed at reducing thrombosis and bleeding risks as a direction that includes the development of existing medical devices such as T-TAS.